A PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF INTRAVENOUS INFUSION WITH HUMAN SOLUBLE RECOMBINANT FC-GAMMA RECEPTOR IIB (SM101/ BAX 1810) IN SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
- Registry ID
- 181501
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- BAXALTA US INC
- Last update
- 2015-11-06
Conditions
- IMMUNOGLOBULIN A NEPHROPATHY
Related clinical trials
- A PHASE 2B, MULTICENTER, OPEN-LABEL, SINGLE-ARM TRIAL TO EVALUATE THE IMPACT OF SIBEPRENLIMAB ON KIDNEY HISTOPATHOLOGY THROUGH REPEAT KIDNEY BIOPSIES IN ADOLESCENTS AND ADULTS WITH IMMUNOGLOBULIN A NEPHROPATHY
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF POVETACICEPT
IN ADULTS WITH IMMUNOGLOBULIN A NEPHROPATHY (RAINIER)
- A PHASE 2/3, MULTICENTER, OPEN LABEL TRIAL TO EVALUATE THE LONG TERM SAFETY, TOLERABILITY, AND EFFICACY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VIS649 IN PARTICIPANTS WITH IMMUNOGLOBULIN A (IGA) NEPHROPATHY.
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE SAFETY AND EFFICACY OF OMS721 IN PATIENTS WITH IMMUNOGLOBULIN A (IGA) NEPHROPATHY (ARTEMIS-IGAN)
View on source registry